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Elevated intraocular pressure (IOP) is one of the main 
factors contributing to glaucoma pathology. Elevation of 
IOP is mainly due to resistance in aqueous humor outflow 
in the trabecular meshwork and the uveoscleral pathway [1], 
after being produced in the ciliary body [2]. Most models 
displaying ocular hypertension and glaucoma require 
physical, chemical, or surgical animal modifications to trans-
form the models from normotensive into hypertensive [3,4]. 
Nonetheless, for several years, a mouse strain classified as 
DBA/2J has been used as the model for glaucoma because 
this model develops the pathology spontaneously. These 
animals present several mutations in the genes Tyrp1 and 
Gpnmb, which encode for tyrosinase-related and glycosylated 
transmembrane proteins, respectively. Consequently, these 
mice present iris pigment dispersion, iris transillumination 
as well as iris atrophy, and anterior synechia [5]. The pigment 
dispersion likely is responsible for the blockade of aqueous 
outflow, which generates ocular hypertension at 9 months 
of age. This rise in IOP is accompanied by the canonical 
symptoms of glaucoma-related disease, including the death 
of retinal ganglion cells (RGCs), optic nerve atrophy and 
cupping, and visual deficits [6]. Altogether, these symptoms 
lead to progressive optic neuropathy characterized by func-
tional and structural impairment of ocular tissues that may 
result in vision loss [7].
Many new compounds, apart from those already 
commercially available, have appeared attempting to 
provide effective treatments to stop ocular hypertension and 
glaucoma progression [8]. One of the emerging compounds 
is melatonin and its analogs, which clearly present ocular 
hypotensive effects, as well as interesting neuroprotective 
actions [9,10]. Melatonin is present naturally in the aqueous 
humor and may regulate IOP physiologically [11]. Melatonin 
and some of its analogs, such as 5-methoxycarbonylamino-
N-acetyltryptamine (5-MCA-NAT), when topically applied, 
can produce a marked reduction in IOP [12-14,15]. The action 
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Purpose: The objective of this study was to evaluate the changes in the melatoninergic receptors of DBA/2J and 
C57BL/6J mice with the development of glaucoma. DBA/2J mice are widely used to study the physiopathology of 
glaucoma due to the similarities of their eyes to human eyes and the resulting similarity in the development of their 
pathology. In addition, melatoninergic receptors are known for their control of intraocular pressure (IOP), reducing the 
production of aqueous humor; however, little is known about their relationship with the development of this pathology.
Methods: mRNA expression of MT1, MT2, and GPR50 melatoninergic receptors was performed with quantitative 
real-time PCR. In addition, receptor expression was performed with immunohistochemical techniques on the ciliary 
processes. To further investigate the effect of melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine 
(5-MCA-NAT) on IOP, animals were instilled with these compounds and the corresponding melatoninergic antagonists 
to assess their effect on IOP.
Results: All melatoninergic receptor expression decayed with the development of the glaucomatous pathology in the 
DBA/2J mice, and was especially visible for the MT2 receptor. However, receptor expression was consistent in the 
C57BL/6J control mice across all ages investigated. Furthermore, IOP blockage was stronger with 4PPDOT (MT2 an-
tagonist) only in the DBA/2J mice which suggests a correlation of this receptor with the development of the glaucomatous 
pathology in DBA/2J animals.
Conclusions: Melatonin receptor expression decays with the development of the glaucomatous pathology. This implies 
that the physiologic hypotensive effect of endogenous melatonin reducing IOP is not possible. A solution for such changes 
in receptor expression is the exogenous application of melatonin or any of its analogs that permit the activation of the 
remaining melatonin receptors.
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of melatoninergic agents is mediated by membrane proteins 
termed MT1 and MT2 and the putative MT3 receptors [14]. In 
addition, the GPR50 protein has been identified as a possible 
melatonin receptor due to its homology with MT1 and MT2 
receptors [16], although this protein has not yet been proved 
to be activated by melatonin. The presence of such receptors 
is widespread in the eye, and in particular, MT1 and MT2, are 
present in the ciliary body, the tissue where aqueous humor 
is produced [17].
Experiments preformed in normotensive rabbits have 
demonstrated that melatonin and 5-MCA-NAT can reduce 
the chloride and water outflow the from ciliary body epithe-
lial cells, this being the reason for the observed decrease in 
IOP when those melatoninergic agents are applied [18]. We 
also found that melatonin analogs could reduce IOP in the 
DBA/2J mouse glaucoma model. This is particularly inter-
esting because the hypotensive effect is especially relevant 
when the animal has fully developed the pathology, which 
occurs from 9 months of age. Moreover, when treatment with 
the analog 5-MCA-NAT is performed chronically, the typical 
rise in IOP observed from 9 months of age does not progress, 
and IOP remains consistent [19].
Little is known about why IOP rises when the glauco-
matous pathology is established. It could be that among other 
factors, the endogenous melatonin present in the aqueous 
humor was unable to produce the physiologic control of IOP 
due to a change in the presence of melatonin receptors. To 
investigate this possibility, in the present study we measured 
changes in the expression of melatonin receptors according 
to time intervals in control (C57BL/6J) and DBA/2J mice, 
observing a decrease in melatonin receptors in the glauco-
matous mice but not in the control mice.
METHODS
Animals: Experiments were performed on adult female 
C57BL/6J (control animals) and DBA/2J (glaucomatous 
animals) mice obtained from the European distributor of 
Jackson Laboratories Mice (Charles River Laboratories, 
Saint-Germain-Nuelles, France). All animal maintenance 
and experimental procedures followed Spanish and Euro-
pean guidelines for animal care in the laboratory and 
animal research (Guide for the Care and Use of Laboratory 
Animals) and the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research. Mice were housed (one 
to four mice per cage) in temperature- and light-controlled 
rooms maintained according to a 12 h:12 h light-dark cycle; 
all animals were fed ad libitum. The DBA/2J and C57BL/6J 
mice were examined at 3, 6, 9, and 12 months of age. The 
study was approved by the Animal Experimental Committee 
of the Universidad Complutense de Madrid and Comunidad 
de Madrid, reference 45/057949.9/16.
Study design: A total of 48 animals of each strain were 
used for the study. Among them, 24 were used for PCR (six 
animals at each time point: 3, 6, 9, and 12 months), 12 for 
immunofluorescence (six animals at 3 and 12 months), and 
12 for IOP measurements.
RNA isolation and RT–PCR: Total RNA from isolated ciliary 
bodies and irises of the DBA/2J (n = 24) and C57BL/6 (n 
= 24) mice was extracted using the SpeedTools total RNA 
extraction kit (Biotools, Madrid, Spain), following the 
manufacturer’s instructions. After digestion with TURBO 
DNase (Ambion, Austin, TX), total RNA was quantified and 
reverse-transcribed using M-MLV reverse transcriptase, 6 µg 
of random primers, and 350 µM deoxynucleotides (dNTPs; 
Invitrogen, San Francisco, CA). Due to the small size of the 
tissues, and to improve the sensitivity of the PCR analysis, 
preamplification reactions were performed using DNA 
AmpliTools Master Mix (Biotools), 5 µl of the reverse tran-
scriptases (RT) product, and specific commercial oligonucle-
otide primers for mouse MT1, MT2, and GPR50 receptors 
(Applied Biosystems). Non-template control was amplified 
to check for contamination during the procedure. Preampli-
fication reactions were performed on a 2720 Thermal Cycler 
(Applied Biosystems) with the following program: the initial 
denaturation step at 94 °C for 5 min followed by 14 cycles of 
amplification (94 °C for 30 s; 60 °C for 30 s; and 72 °C for 30 
s). Then, 5 μl of the preamplified product diluted 1:5 in water 
were used for the subsequent PCR assay. The PCR reactions 
were identical to the preamplification reactions, with the 
exception of the number of cycles, which was 40 in the last 
case. The amplified PCR products were electrophoresed on 
a 2% agarose gel and visualized with SYBR® Safe DNA gel 
stain (Invitrogen). The DNA ladders used were GeneRuler 1 
kb and 100 bp (Thermo Scientific).
Quantitative real-time PCR: Following preamplification, 
5 μl of each product diluted 1:5 in water were used for 
the subsequent quantitative real-time PCR assay (qPCR). 
qPCR reactions were performed using LuminoCt® qPCR 
ReadyMix (Sigma-Aldrich), 5 µl of the RT product, and 
specific commercial oligonucleotide primers and TaqMan 
MGB probes for the mouse MT1, MT2, and GPR50 recep-
tors, as well as for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; all from Applied Biosystems). Fast thermal 
cycling was performed using a StepOnePlus® Real-Time 
System (Applied Biosystems, Foster City, CA) as follows: 
denaturation, one cycle of 95 °C for 20 s, followed by 40 
cycles each of 95 °C for 1 s and 60 °C for 20 s. The results 
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were normalized as indicated by parallel amplification of the 
GAPDH housekeeping gene.
Immunohistochemistry: C57BL/6J and DBA/2J mice at 3 
and 12 months of age (n = 6 animals for each group) were 
euthanized with an intraperitoneal injection of 20% sodium 
pentobarbital (Dolethal, Vetoquinol®; Especialidades Veteri-
narias, S.A., Alcobendas, Madrid, Spain) and perfused peri-
cardially with PBS (1X; 137 mM NaCl, 2.68 mM KCl, 8.1 
mM Na2HPO4, 1.47 mM KH2PO4, pH 7.3) followed by a solu-
tion of 4% paraformaldehyde in PBS 0.1 M, pH 7.4 at 4 °C. 
The eyes were enucleated and dissected with curved forceps 
and sterile scissors. The anterior pole was immersed in para-
formaldehyde (PFA) fixative solution for 1 h at 4 °C, washed 
in PBS, rinsed in 11% sucrose solution for 1 h, and placed 
in 33% sucrose solution overnight at 4 °C as the cryopro-
tection procedure. Finally, the structures were embedded in 
tissue medium freezing medium (Tissue-Tek© OCT, Sakura 
Finetek, Torrance, CA) using liquid dinitrogen. Vertical 
sections (10 μm thick) were cut on a cryostat (Microm, Wall-
dorf, Germany) and collected on poly-L lysine-coated slides 
and stored at −20 °C until use.
The frozen sections were rinsed in PBS 1X and permea-
bilized with PBS containing 0.25% Triton X-100 (TX-100) 
for 30 min. To avoid non-specific staining, the sections were 
incubated with blocking solution containing 10% normal 
donkey serum (NDS; Jackson ImmunoResearch, West Grove, 
PA) and 0.1% TX-100 in PBS for 1 h at room temperature. 
Then, the following primary antibodies diluted in PBS 
containing 0.1% TX-100 were incubated at 4 °C overnight: 
goat anti-MT1 (Santa Cruz Biotechnologies, Inc. Santa Cruz, 
CA; sc-15204, 1:100), goat anti-MT2 (Alomone Labs, Jeru-
salem, Israel; APR-010, 1:100), and goat anti-GPR50 (Santa 
Cruz Biotechnologies; sc-15215, 1:75). The tissue sections 
were then washed in PBS containing 0.1% TX-100 and incu-
bated with the secondary antibody donkey anti-rabbit Alexa 
Fluor 488 immunoglobulin G (IgG; H+L; Jackson ImmunoRe-
search) diluted 1:200 in PBS containing 0.1% TX-0.1% for 1 
h in darkness at room temperature. The nuclei were stained 
with propidium iodide (red, Sigma-Aldrich, St. Louis, MO) 
diluted 1:500 in PBS for 10 min. Finally, the sections were 
rinsed and mounted in Vectashield (Vector Laboratories, 
Palex Medical, Barcelona, Spain) and coverslipped. For the 
analysis, images were acquired using a laser-scanning micro-
scope (Zeiss LSM 5, Jena, Germany) at 40X magnification 
and exported as .tiff layers for further analysis.
IOP measurements: Melatonin (Sigma) and 5-MCA-NAT 
(Tocris, Bristol, UK) were formulated in isotonic saline 
containing 1% dimethyl sulfoxide (DMSO; Sigma, Darm-
stadt, Germany) and tested at 100 µM. The substances were 
applied in drops to the cornea at a fixed volume of 2 µl in 
both eyes. The control animals received the same volume of 
saline + 1% DMSO. IOP was measured with a TonoLab® non-
invasive rebound tonometer supplied by Tiolat Oy (Vantaa, 
Finland). To avoid the effect of the circadian rhythm, the IOP 
was always tested at the same time of the day. Six consecutive 
measurements were taken for each reading, and three read-
ings were obtained for each eye.
To study the effect of melatonin and 5-MCA-NAT, two 
IOP measurements were taken before they were instilled, 
and once every hour for 6 consecutive h. Luzindole (a non-
selective melatonin antagonist), 4-phenyl-2- propionamidot-
etralin (4PPDOT, an MT2 melatonin antagonist), and prazosin 
(a MT3 melatonin antagonist) were used as antagonists of the 
melatonin receptors, all tested at 100 µM. To study the effect 
of the different antagonists tested, they were instilled at a 
volume of 2 µl, 30 min before the agonist, at a concentration 
of 100 µM. IOP was measured in the same fashion as previ-
ously described [19].
Statistical analysis: All data are presented as the mean ± 
standard error of the mean (SEM). Statistical differences were 
calculated using one-way analysis of variance (ANOVA) test 
with Dunnett’s multiple comparisons test. Plotting and fitting 
were performed with GraphPad Prism 6 computer program 
(GraphPad Software, San Diego, CA).
RESULTS
Expression of melatonin receptors in murine ciliary 
processes: We performed RT–PCR experiments demon-
strating that MT1, MT2, and GPR50 transcripts are expressed 
in the ciliary processes of C57BL/6J and DBA/2J mice. These 
results indicated that the expression levels of melatonin recep-
tors were presented in the control and glaucomatous animals. 
Taking into account that the intensity appeared different 
between the two mice strains, we analyzed the expression of 
the MT1, MT2, and GPR50 receptors in the ciliary processes 
of the C57BL/6J and DBA/2J mice at different ages with 
qPCR and immunohistochemistry to check whether there 
was any change.
Expression of the melatonin MT1 receptor in the ciliary 
body: The qPCR results for the non-glaucomatous mouse 
(C57BL/6J) ciliary body revealed that the expression of the 
MT1 mRNA remained consistent at 3, 6, 9, and 12 months 
of age (Figure 1A, black bars). Interestingly, when the same 
type of analysis was performed in the glaucomatous DBA/2J 
mice, the MT1 transcript level was 2.2-fold greater in the 
3-month-old DBA/2J mice compared to the control C57BL/6J 
at the same age (p<0.001), decreasing with the progression 
of the pathology during the following months (Figure 1A, 
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orange bars). The reduction was the highest at 12 months of 
age which is 1.7-fold smaller than in the 3-month-old DBA/2J 
mice.
Immunohistochemistry demonstrated the presence of the 
MT1 receptor in the non-pigmented epithelium of the ciliary 
processes of the C57BL/6J and DBA/2J animals. The fluo-
rescence was very intense in the 3-month-old DBA/2J mice 
compared to the 12-month-old animals (Figure 1B), which 
seems to indicate that there is also a reduction at the protein 
level with the development of the pathology.
Expression of the melatonin MT2 receptor in the ciliary body: 
The expression pattern of the MT2 receptor was very similar 
to that observed for the MT1 melatonin receptor. As shown 
in Figure 2A, the MT2 receptor transcript levels remained 
constant in the C57BL/6J mice (black bars), but an age-
dependent decrease in the MT2 receptor mRNA was observed 
in the DBA/2J mice (blue bars). This reduction was signifi-
cant from 6-month-old animals in advance, as the maximum 
expression at 3 months of age, before the pathology starts, and 
the minimal at 12 months was 8.9-fold lower.
Immunohistochemistry confirmed that the MT2 receptor 
was also located in the non-pigmented epithelium of the 
ciliary body in both mouse strains. Moreover, the fluores-
cence of the MT2 receptor was statistically significantly 
higher in the 3-month-old DBA/2J animals compared to the 
older ones and compared to the young C57BL/6 mice (Figure 
2B).
Expression of the GPR50 receptor in the ciliary body: The 
expression levels of the GPR50 transcript were compared 
between the control and glaucomatous mice in the same 
way as the other melatonin receptors described above. In the 
C57BL/6J mice, the mRNA expression of GPR50 remained 
consistent during the adult life of the animals (Figure 3A, 
black bars). Additionally, expression of GPR50 in the DBA/2J 
mice was fourfold higher than that in the C57BL/6J animals 
at 3 months old (p<0.001), but decreased to control values 
in older mice (Figure 3A, purple bars), with the minimum 
expression 2.5-fold smaller when the mice were 12 months 
old.
Immunohistochemistry revealed that the GPR50 receptor 
is widely distributed over all in the non-pigmented epithelium 
of the ciliary processes of the eye in the C57BL/6 and DBA/2J 
mice. As observed, the fluorescence of the GPR50 receptor 
was also enhanced in the 3-month-old DBA/2J animals 
compared to the 12-month-old mice and to the 3-month-old 
C57BL/6 mice (Figure 3B).
Activation of melatonin receptors decreases IOP in C57BL/6J 
and DBA/2J mouse strains: The action of melatonin and 
its analog 5-MCA-NAT was tested on the C57BL/6J and 
glaucomatous DBA/2J aged mice. As can be observed in 
Figure 4A (left), in non-glaucomatous animals, melatonin 
produced a reduction in IOP of 18.7±3.70% when compared 
to the control mice (vehicle; n = 6, *p<0.05 versus control; 
one-way ANOVA with Dunnett’s multiple comparisons test). 
The application of melatonin receptor antagonists, such as 
luzindole (non-selective MT1/MT2), 4-PPDOT (MT2), and 
prazosin (MT3 and α1-adrenergic antagonist), reversed the 
hypotensive effect of melatonin suggesting that melatonin 
acts on the different receptors present in the ciliary body. 
To discard the involvement of alpha-adrenergic receptors due 
to the use of prazosin, the selective α1-adrenergic antago-
nist corynanthine was tested. As shown in Figure 4A, this 
compound did not modify IOP statistically significantly when 
melatonin was present.
When melatonin was topically applied in the glaucoma-
tous DBA/2J mice, a strong reduction in IOP was observed 
(36.2±5.90%, n = 6, **p<0.01 versus control; one-way 
ANOVA with Dunnett’s multiple comparisons test; Figure 
4A, right). When the same antagonists for melatonin recep-
tors were applied in the DBA/2J mice, only luzindole and 
4-PPDOT were able to antagonize the hypotensive effect 
of melatonin. Prazosin produced some reversion, but the 
value was not statistically significant. In the C57BL/6J mice, 
corynanthine did not produce any change in the IOP.
When the melatonin analog 5-MCA-NAT was used in 
non-glaucomatous mice, it was possible to observe a reduc-
tion of 20.4±2.80% in IOP when compared to the control mice 
(Figure 4B, left; n = 6, **p<0.01 versus control; one-way 
ANOVA with Dunnett’s multiple comparisons test). The 
application of the antagonists luzindole, 4-PPDOT, and 
Prazosin completely reversed the 5-MCA-NAT effect.
In the DBA/2J mice, the effect of 5-MCA-NAT dimin-
ishing IOP was also observed (32.5±4.30% n = 6, **p<0.01 
versus control; one-way ANOVA with Dunnett’s multiple 
comparisons test). Interestingly, when the three melatonin 
receptor antagonists were assayed, only the selective MT2 
antagonist 4-PPDOT was able to statistically significantly 
reverse the effect of 5-MCA-NAT (27.71±11.70%, n = 6, 
*p<0.05 versus control; one-way ANOVA with Dunnett’s 
multiple comparisons test). The other two agonists showed 
a trend, but the differences were not statistically significant 
(Figure 4B, right).
DISCUSSION
The present study showed changes in the melatonin recep-
tors MT1 and MT2 and the protein GPR50 expression in the 
ciliary body of a model of glaucoma, observed in the DBA/2J 
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Figure 1. Temporal pattern of MT1 mRNA expression and cellular distribution of the MT1 receptor (in ciliary processes of C57BL/6J versus 
DBA/2J mice). A: Total RNA from ciliary processes of either control (C57BL/6J) or glaucomatous (DBA/2J) animals of 3, 6, 9, or 12 
months of age was extracted, and MT1 mRNA was quantified with quantitative real-time PCR (qPCR) as described in the Methods section. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for the differences in the cDNA input. Results are the mean ± 
standard error of the mean (SEM) of 24 animals of each strain (*p<0.05, **p<0.01 versus the same mouse strain; #p<0.05, ###p<0.001 versus 
a different mouse strain; one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test). B: Immunofluorescence images 
of ciliary processes from 3-month-old C57BL/6J (I), 3-month-old DBA/2J (II), and 12-month-old DBA/2J (III) mice labeled with antibodies 
against the MT1 receptor (green). Nuclei were counterstained with propidium iodide (red). Phase-contrast and confocal images show that 
the MT1 receptor is mainly located in the non-pigmented epithelium of the ciliary processes, and expression of the receptor is increased in 
the DBA/2J versus C57BL/6J mice at the age of 3 months. Scale bar = 20 μm.
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Figure 2. Temporal pattern of MT2 mRNA expression and cellular distribution of MT2 receptor in ciliary processes of C57BL/6J versus 
DBA/2J mice. A: Total RNA from the ciliary processes of either control (C57BL/6J) or glaucomatous (DBA/2J) animals at 3, 6, 9, or 12 
months of age was extracted, and MT2 mRNA was quantified with quantitative real-time PCR (qPCR) as described in the Methods section. 
Values were normalized to the content of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript. Results are the mean ± stan-
dard error of the mean (SEM) of 24 animals of each strain (***p<0.001 versus the same mouse strain; #p<0.05, ###p<0.001 versus a different 
mouse strain; one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test). B: Immunofluorescence images of ciliary 
processes from 3-month-old C57BL/6J (I), 3-month-old DBA/2J (II), and 12-month-old DBA/2J (III) mice labeled with antibodies against 
the MT2 receptor (green). Nuclei were counterstained with propidium iodide (red). Phase-contrast and confocal images show that the MT2 
receptor is mainly located in the non-pigmented epithelium of the ciliary processes, and expression of the receptor is strongly increased in 
the 3-month-old DBA/2J mice compared to the older mice and to the 3-month-old C57BL/6J mice. Scale bar = 20 μm.
Molecular Vision 2020; 26:530-539 <http://www.molvis.org/molvis/v26/530> © 2020 Molecular Vision 
536
Figure 3. Temporal pattern of GPR50 mRNA expression and cellular distribution of GPR50 receptor in ciliary processes of C57BL/6J 
versus DBA/2J mice. A: Total RNA from the ciliary processes of either control (C57BL/6J) or glaucomatous (DBA/2J) animals at 3, 6, 9, 
or 12 months of age was extracted, and GPR50 mRNA was quantified with quantitative real-time PCR (qPCR) as described in the Methods 
section. Values were normalized to the content of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript. Results are the mean 
± standard error of the mean (SEM) of 24 animals of each strain (*p<0.05, ***p<0.001 versus the same mouse strain; #p<0.05, ###p<0.001 
versus a different mouse strain; one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test). B: Immunofluorescence 
images of the ciliary processes from 3-month-old C57BL/6J (I), 3-month-old DBA/2J (II), and 12-month-old DBA/2J (III) mice labeled 
with antibodies against the GPR50 receptor (green). Nuclei were counterstained with propidium iodide (red). Phase-contrast and confocal 
images show that GPR50 immunostaining is mainly located in the non-pigmented epithelium of the ciliary processes, and enhanced in the 
DBA/2J mice versus the C57BL/6J mice at the age of 3 months. Scale bar = 20 μm.
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mouse. Compared with the control animals (the C57BL/6J 
mouse strain), the DBA/2J mice presented a clear reduction in 
the mRNA expression of all the receptors investigated, which 
decreased concomitantly with the advance of the pathology.
The importance of melatonin receptors in the ciliary 
body is related to their role in control of the homeostasis of 
aqueous humor. The presence of the melatonin MT1 and MT2 
receptors and the putative MT3 receptors in the ciliary body 
has been described in various models [14,20-22], including 
those involved in homeostasis of aqueous humor. Melatonin 
in aqueous humor must be present for their activation. In 
this regard, melatonin’s presence in this humor has been 
known since the mid-1990s [17,23]. Several research groups 
have examined the levels of melatonin in this ocular fluid 
[11,24], but only recently has it been possible to demonstrate 
that in the case of elevated IOP, melatonin concentrations are 
also high. Changes related to ocular hypertension have been 
observed in humans and in DBA/2J mice, where the levels 
of melatonin in aqueous humor present a fourfold increase 
[25]. This increase in melatonin concentration together with 
the elevation in IOP indicates a kind of uncoupling between 
endogenous melatonin concentrations (nM) and the receptors, 
as it has been demonstrated that the application of exogenous 
melatonin concentrations (µM) can reduce IOP in normoten-
sive and hypertensive models, including the model used in 
this study [19,22]. In ocular hypertensive situations, it was 
recently demonstrated that a TRPV4 channel is in control of 
melatonin synthesis in the ciliary body [26]. This channel 
acts as a pressure sensor that can stimulate expression of the 
key enzyme in melatonin synthesis, arylalkymine N-acetyl-
transferase (AANAT) [27], as well as its phosphorylation, 
both mechanisms promoting the synthesis of melatonin in 
the ciliary body [28].
The present results offer an explanation for why the 
elevated melatonin levels in the IOP of glaucomatous mice 
remain high. In this instance, we demonstrated a reduction 
in the expression of mRNA melatonin receptors in the ciliary 
body that may explain why although the concentrations in the 
aqueous humor of this substance are increased, there is not 
enough to reduce the IOP. The experiments performed in the 
DBA/2J model applying melatonin at micromolar concentra-
tions were capable of producing short- and long-term effects 
on IOP. However, melatonin was able to produce a reduction 
of about 20% in IOP detectable for a few hours. This effect 
was more intense in the melatonin analog 5-MCA-NAT, and 
this compound was able to stop the elevation of IOP when 
applied chronically for 3 months [19]. These two facts indicate 
that the receptors are still active, but higher concentrations of 
melatonin are needed to produce the hypotensive effect.
Although protein expression detected with immuno-
fluorescence seems to be decreased in DBA/2J mice with the 
development of the pathology, it could not necessarily have 
Figure 4. Effect of melatonin receptor antagonists on IOP reduction mediated by melatonin and 5-MCA-NAT in C57BL/6J (dark bars) versus 
DBA/2J (light bars) mice at 9 months old. Two intraocular pressure (IOP) measurements were taken before a single dose of either vehicle or 
100 μM melatonin (A) or 5-MCA-NAT (B) was applied, and 3 h later, the IOP was measured again. When indicated, melatonin antagonists, 
all tested at 100 μM, were instilled 30 min before the agonist. Luzindole is a non-selective melatonin antagonist; 4-phenyl-2- propionami-
dotetralin (4PPDOT) is a MT2 melatonin antagonist, prazosin is a MT3 melatonin antagonist/alpha blocker, and corynanthine is an alpha 
blocker. Data are the mean ± standard error of the mean (SEM) of four mice (*p<0.05, **p<0.01, ***p<0.001 versus agonist compound of 
each strain; one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test). One hundred percent were calculated as 
the values of the control C57BL/6J mice.
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the same difference found at the mRNA level. Possible non-
specific staining could not be discarded [29] with the present 
results and should be confirmed in future experiments to 
ensure that the strong decrease at the mRNA level translates 
into protein expression.
Among the three proteins under investigation, the 
melatonin MT2 receptor seems to be the most affected by 
the reduction in the receptor’s mRNA expression levels. This 
may explain in part why melatonin is unable to reduce IOP. 
Nevertheless, the melatonin MT1 receptor changes should 
also be considered. Experiments performed on MT1 knockout 
(KO) mice showed clear elevations in IOP [30], with severe 
changes in retinal ganglion cell survival [31]. Moreover, it is 
important to bear in mind that the GPR50 orphan receptor, 
which shares 45% of homology with melatonin receptors, 
has a close relation with melatonin receptors. Although the 
GPR50 receptor does not seem to be a melatonin receptor, 
being more related to energy metabolism [32], this receptor 
can form heterodimers with MT1 and MT2 receptors [33]. As a 
result of such dimerization, the activity of the MT1 melatonin 
receptor gets inhibited, while the dimer with the MT2 receptor 
does not affect its activity [34]. As in the present study the 
expression of mRNA GPR50 decreased with the develop-
ment of the pathology, and considering previous comments 
about heteromerization, the melatonin MT1 receptor would be 
disadvantaged in its total effect on IOP, by the reduction of 
the expression of the receptor and by the possible dimeriza-
tion with the GPR50 protein.
In conclusion, expression of melatonin mRNA receptors 
decays with the development of the glaucomatous pathology. 
This implies that the physiologic hypotensive effect of endog-
enous melatonin reducing IOP is not possible. A solution for 
such changes in receptor expression is the exogenous applica-
tion of melatonin or any of its analogs to permit the activation 
of the remaining melatonin receptors.
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